(-)-DDMS (S-Didesmethylsibutramine, (S)-DDMS) is one of sibutramine active metabolites. Sibutramine is widely used in the treatment of obesity. Sibutramine acts by inhibiting the reuptake of serotonin and noradrenaline in synapses, thereby enhancing both satiety and energy expenditure. In preclinical models (S)-Didesmethylsibutramine affected locomotor behavior and the Porsolt test but appeared to be completely inactive on food intake. (S)-enantiomers of didesmethylsibutramine may, to some extent, contribute to sibutramine’s side effect profile.

TAK-779 is a selective antagonist of CCR5 receptor, which was initially developed by Takeda for the treatment of HIV infection. However, the development was terminated due to poor oral bioavailability. Also, TAK-779 demonstrated the ability to protect the brain against focal cerebral ischemia in mice.

PPACK is a synthetic peptide that irreversibly inhibits thrombin-mediated platelet activation by binding to the active site of thrombin with a Ki = 0.24 nM. PPACK competes with alpha-thrombin at the high-affinity site and is an antagonist of alpha-thrombin induced activation. PPACK is used as a tool for assessment of Platelet function.

Magnesium Selenite is mostly insoluble in water Magnesium salt.